

Pfizer Brought into a Depo-Provera Meningioma Claim in Clark County, WA

LOS ANGELES, CA, UNITED STATES, June 3, 2026 /EINPresswire.com/ -- "Our client was prescribed Depo-Provera both before and after being diagnosed with a meningioma. The use of Depo-Provera caused the meningioma to grow, ultimately necessitating a craniotomy. Pfizer is named as a defendant in this claim."

[Dr. Greg Vigna, MD, JD](#), states, "By 2018, Pfizer had reason to issue a Dear Doctor Letter warning of the risk of meningioma growth and recurrence associated with the continued use of Depo-Provera. However, they did not."

Dr. Vigna concludes, "Depo-Provera may be associated with an increased risk of meningioma, and this risk could have potentially been avoided through the use of traditional birth control pills. In this case, we have also named the prescribing physician, who continued prescribing the drug after the meningioma diagnosis was known, which may have contributed to further tumor growth and ultimately led to the need for a craniotomy (brain surgery)."



Dr. Greg Vigna

Case No. 25-2-04507-06

Discover crucial insights by watching Dr. Vigna's educational episode on Justice with Dr. V. This delves into the symptoms associated with Depo-Provera and [meningiomas](#), providing essential information to guide your health decisions: [Depo-Provera and Meningioma Risk: What the FDA Warning Means](#)

Watch Justice with Dr. V on TikTok to learn more about Depo-Provera: https://www.tiktok.com/@vignallawgroup?is_from_webapp=1&sender_device=pc

Dr. Vigna is a California and Washington D.C., lawyer and is Co-Counsel with the Ben Martin Law

Group, a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent women who have suffered meningiomas.

California Offices:

8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045

2570 N. First Street, 2nd Floor, San Jose, CA 95131

931 10th Street, #962, Modesto, CA 95354

2281 Lava Ridge Court, Suite 200, Roseville, CA 95661

600 West Broadway, Suite 700, San Diego, CA 92101

Case No. 25-2-04507-06

20 2.68 Despite the above-described knowledge about and overwhelming evidence of the
21 dangers of Depo-Provera and DMPA, the Manufacturer Defendants misrepresented to the
22 medical community and end users, including Plaintiff, that Depo-Provera and DMPA were
23 appropriate, safe, and effective for long-term contraceptive use. Such misrepresentations were
24 made through the Manufacturer Defendants' labeling, packaging, advertising, and patient inserts
25 included with their Depo-Provera and DMPA products. The Manufacturer Defendants also failed
26 to warn U.S. consumers, end users, and healthcare providers about the increased risk of
1 meningiomas, instead suppressing the true risks of Depo-Provera and DMPA and overstating the
2 benefits through various means and media. The Manufacturer Defendants further under- and



Depo-Provera may be associated with an increased risk of meningioma, and this risk could have potentially been avoided through the use of traditional birth control pills."

Greg Vigna, MD, JD

Connecticut Office:

515 Centerpoint Drive, Suite #2212, Middletown, CT 06457

Greg Vigna, MD, JD

Vigna Law Group

+1 817-809-9023

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/917121037>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.